The kidney disease market size has grown strongly in recent years. It will grow from $99.22 billion in 2023 to $106.6 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth observed in the historical period can be attributed to several factors, including the increasing prevalence of chronic health conditions, an aging population, genetic predisposition to kidney diseases, advancements in medical research and education, and the influence of environmental factors.
The kidney disease market size is expected to see strong growth in the next few years. It will grow to $136.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The anticipated growth in the forecast period can be attributed to various factors, including the global management of infectious diseases, the adoption of precision medicine approaches in kidney care, the epidemic of diabetes and obesity, changes in healthcare policies, and increased awareness and screening for kidney-related conditions. Notable trends expected in the forecast period encompass the use of telemedicine in kidney care, a heightened focus on preventive nephrology, an increase in home-based dialysis options, the development of regenerative therapies, and the emphasis on dietary modifications and nutrition for kidney health.
The anticipated increase in the incidence of kidney diseases is expected to drive the growth of the kidney disease market. Kidney diseases encompass a range of conditions affecting the structure and function of the kidneys. Medications for kidney disorders play a crucial role in managing symptoms, reducing protein loss, and slowing the progression of kidney damage, ultimately preventing complications. In June 2023, Kidney Research UK reported that an estimated 7.19 million people in the UK were affected by chronic kidney disease, representing over 10% of the population and projected to rise to 7.61 million people by 2033. Therefore, the heightened incidence of kidney diseases serves as a significant driver propelling the growth of the kidney disease market.
The increasing prevalence of high blood pressure and diabetes is expected to contribute significantly to the growth of the kidney disease market. High blood pressure, characterized by elevated blood force against arterial walls, and diabetes, a metabolic disorder leading to high blood glucose levels, are major contributors to kidney diseases. The sustained damage caused by high blood pressure and diabetes to the small blood vessels in the kidneys can result in kidney damage, impacting their ability to effectively filter waste and excess fluids from the blood. According to the National Diabetes Statistics Report, approximately 38.4 million people in the United States will have diabetes in 2023, constituting 11.6% of the population. Therefore, the increasing prevalence of high blood pressure and diabetes is a driving force behind the growth of the kidney disease market.
An emerging trend gaining traction in the kidney disease market is the integration of AI-driven tools. Companies in the kidney disease market are adopting new technologies, particularly AI solutions, to enhance patient outcomes and maintain their competitive edge. For instance, Carenostics, a US-based healthcare startup specializing in AI solutions, has introduced a product designed to analyze electronic health record (EHR) data for the early identification of chronic kidney disease (CKD). By seamlessly integrating AI-powered clinical decision support models into healthcare providers' EHR systems, Carenostics empowers clinicians to accurately identify high-risk patients with chronic diseases, facilitating proactive measures for improved patient outcomes.
Major companies in the kidney disease market are adopting a strategic partnership approach to enhance patient care, drive innovation, and expedite the commercialization of therapies. Southern California Kidney Consultants Inc., a US-based medical practices company, has partnered with Strive Health, a US-based healthcare company, to improve kidney disease treatment and care. The partnership involves 21 providers primarily based in Orange County, serving 5,000 patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD).
In January 2023, AstraZeneca Pharmaceuticals LP, a US-based biopharmaceutical company, completed the acquisition of CinCor Pharma Inc. for $1.8 billion. This strategic move enables AstraZeneca to bolster its cardiorenal portfolio by incorporating CinCor's promising compound, baxdrostat (CIN-107). Baxdrostat, an aldosterone synthase inhibitor (ASI), is designed to lower blood pressure in patients with treatment-resistant hypertension, including those with chronic kidney disease. CinCor Pharma Inc. is a US-based clinical-stage biopharmaceutical company specializing in kidney disease medications and treatments.
Major companies operating in the kidney disease market report are Pfizer Inc., Johnson & Johnson Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi Aventis LLC, Bristol-Myers Squibb Company, AstraZeneca Pharmaceuticals LP, Abbott Laboratories, Fresenius SE & Co. KGaA, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Kyowa Kirin Co. Ltd., Cipla Inc., Endo International plc., Lupin Limited, Kissei Pharmaceutical Co. Ltd.
North America was the largest region in the kidney disease market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kidney disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The main types of treatments for kidney disease include medication, dialysis, surgery, and others. Medication involves the use of drugs or pharmaceutical substances to treat, manage, or prevent various medical conditions associated with kidney diseases. These treatments are indicated for conditions such as acute kidney injury, chronic kidney disease, end-stage renal disease, and others, administered through oral and parenteral routes of administration. Various end-users, including hospitals and diagnostic laboratories, utilize these treatments.
The kidney disease research report is one of a series of new reports that provides kidney disease market statistics, including the kidney disease industry's global market size, regional shares, competitors with a kidney disease market share, detailed kidney disease market segments, market trends, and opportunities, and any further data you may need to thrive in the kidney disease industry. This kidney disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The kidney disease market consists of revenues earned by providing services such as hemodialysis, peritoneal dialysis, and kidney transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. The kidney disease also includes sales of drugs such as galafold, sibnayal, tarpeyo, and cystadrops. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The kidney disease market size is expected to see strong growth in the next few years. It will grow to $136.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The anticipated growth in the forecast period can be attributed to various factors, including the global management of infectious diseases, the adoption of precision medicine approaches in kidney care, the epidemic of diabetes and obesity, changes in healthcare policies, and increased awareness and screening for kidney-related conditions. Notable trends expected in the forecast period encompass the use of telemedicine in kidney care, a heightened focus on preventive nephrology, an increase in home-based dialysis options, the development of regenerative therapies, and the emphasis on dietary modifications and nutrition for kidney health.
The anticipated increase in the incidence of kidney diseases is expected to drive the growth of the kidney disease market. Kidney diseases encompass a range of conditions affecting the structure and function of the kidneys. Medications for kidney disorders play a crucial role in managing symptoms, reducing protein loss, and slowing the progression of kidney damage, ultimately preventing complications. In June 2023, Kidney Research UK reported that an estimated 7.19 million people in the UK were affected by chronic kidney disease, representing over 10% of the population and projected to rise to 7.61 million people by 2033. Therefore, the heightened incidence of kidney diseases serves as a significant driver propelling the growth of the kidney disease market.
The increasing prevalence of high blood pressure and diabetes is expected to contribute significantly to the growth of the kidney disease market. High blood pressure, characterized by elevated blood force against arterial walls, and diabetes, a metabolic disorder leading to high blood glucose levels, are major contributors to kidney diseases. The sustained damage caused by high blood pressure and diabetes to the small blood vessels in the kidneys can result in kidney damage, impacting their ability to effectively filter waste and excess fluids from the blood. According to the National Diabetes Statistics Report, approximately 38.4 million people in the United States will have diabetes in 2023, constituting 11.6% of the population. Therefore, the increasing prevalence of high blood pressure and diabetes is a driving force behind the growth of the kidney disease market.
An emerging trend gaining traction in the kidney disease market is the integration of AI-driven tools. Companies in the kidney disease market are adopting new technologies, particularly AI solutions, to enhance patient outcomes and maintain their competitive edge. For instance, Carenostics, a US-based healthcare startup specializing in AI solutions, has introduced a product designed to analyze electronic health record (EHR) data for the early identification of chronic kidney disease (CKD). By seamlessly integrating AI-powered clinical decision support models into healthcare providers' EHR systems, Carenostics empowers clinicians to accurately identify high-risk patients with chronic diseases, facilitating proactive measures for improved patient outcomes.
Major companies in the kidney disease market are adopting a strategic partnership approach to enhance patient care, drive innovation, and expedite the commercialization of therapies. Southern California Kidney Consultants Inc., a US-based medical practices company, has partnered with Strive Health, a US-based healthcare company, to improve kidney disease treatment and care. The partnership involves 21 providers primarily based in Orange County, serving 5,000 patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD).
In January 2023, AstraZeneca Pharmaceuticals LP, a US-based biopharmaceutical company, completed the acquisition of CinCor Pharma Inc. for $1.8 billion. This strategic move enables AstraZeneca to bolster its cardiorenal portfolio by incorporating CinCor's promising compound, baxdrostat (CIN-107). Baxdrostat, an aldosterone synthase inhibitor (ASI), is designed to lower blood pressure in patients with treatment-resistant hypertension, including those with chronic kidney disease. CinCor Pharma Inc. is a US-based clinical-stage biopharmaceutical company specializing in kidney disease medications and treatments.
Major companies operating in the kidney disease market report are Pfizer Inc., Johnson & Johnson Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi Aventis LLC, Bristol-Myers Squibb Company, AstraZeneca Pharmaceuticals LP, Abbott Laboratories, Fresenius SE & Co. KGaA, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Kyowa Kirin Co. Ltd., Cipla Inc., Endo International plc., Lupin Limited, Kissei Pharmaceutical Co. Ltd.
North America was the largest region in the kidney disease market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kidney disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The main types of treatments for kidney disease include medication, dialysis, surgery, and others. Medication involves the use of drugs or pharmaceutical substances to treat, manage, or prevent various medical conditions associated with kidney diseases. These treatments are indicated for conditions such as acute kidney injury, chronic kidney disease, end-stage renal disease, and others, administered through oral and parenteral routes of administration. Various end-users, including hospitals and diagnostic laboratories, utilize these treatments.
The kidney disease research report is one of a series of new reports that provides kidney disease market statistics, including the kidney disease industry's global market size, regional shares, competitors with a kidney disease market share, detailed kidney disease market segments, market trends, and opportunities, and any further data you may need to thrive in the kidney disease industry. This kidney disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The kidney disease market consists of revenues earned by providing services such as hemodialysis, peritoneal dialysis, and kidney transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. The kidney disease also includes sales of drugs such as galafold, sibnayal, tarpeyo, and cystadrops. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Table of Contents
1. Executive Summary2. Kidney Disease Market Characteristics3. Kidney Disease Market Trends and Strategies32. Global Kidney Disease Market Competitive Benchmarking33. Global Kidney Disease Market Competitive Dashboard34. Key Mergers and Acquisitions in the Kidney Disease Market
4. Kidney Disease Market - Macro Economic Scenario
5. Global Kidney Disease Market Size and Growth
6. Kidney Disease Market Segmentation
7. Kidney Disease Market Regional and Country Analysis
8. Asia-Pacific Kidney Disease Market
9. China Kidney Disease Market
10. India Kidney Disease Market
11. Japan Kidney Disease Market
12. Australia Kidney Disease Market
13. Indonesia Kidney Disease Market
14. South Korea Kidney Disease Market
15. Western Europe Kidney Disease Market
16. UK Kidney Disease Market
17. Germany Kidney Disease Market
18. France Kidney Disease Market
19. Italy Kidney Disease Market
20. Spain Kidney Disease Market
21. Eastern Europe Kidney Disease Market
22. Russia Kidney Disease Market
23. North America Kidney Disease Market
24. USA Kidney Disease Market
25. Canada Kidney Disease Market
26. South America Kidney Disease Market
27. Brazil Kidney Disease Market
28. Middle East Kidney Disease Market
29. Africa Kidney Disease Market
30. Kidney Disease Market Competitive Landscape and Company Profiles
31. Kidney Disease Market Other Major and Innovative Companies
35. Kidney Disease Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Kidney Disease Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on kidney disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for kidney disease? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Treatment: Medication; Dialysis; Surgery; Other Treatments
2) By Indication: Acute Kidney Injury; Chronic Kidney Disease; End-Stage Renal Disease; Other Indication
3) By Route Of Administration: Oral; Parenteral
4) By End-user: Hospitals; Diagnostic Laboratories; Other End-Users
Key Companies Mentioned: Pfizer Inc.; Johnson & Johnson Ltd.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc.
- Johnson & Johnson Ltd.
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- AbbVie Inc.
- Bayer AG
- Novartis AG
- Sanofi Aventis LLC
- Bristol-Myers Squibb Company
- AstraZeneca Pharmaceuticals LP
- Abbott Laboratories
- Fresenius SE & Co. KGaA
- GlaxoSmithKline Plc.
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Co Ltd.
- Gilead Sciences Inc.
- Amgen Inc.
- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Ltd.
- Astellas Pharma Inc.
- Vertex Pharmaceuticals Inc.
- Otsuka Pharmaceutical Co. Ltd.
- Mitsubishi Tanabe Pharma Corporation
- Aurobindo Pharma Limited
- Dr. Reddy's Laboratories Ltd.
- Kyowa Kirin Co. Ltd.
- Cipla Inc.
- Endo International plc.
- Lupin Limited
- Kissei Pharmaceutical Co. Ltd.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 106.6 Billion |
| Forecasted Market Value ( USD | $ 136.97 Billion |
| Compound Annual Growth Rate | 6.5% |
| Regions Covered | Global |
